Proofs of concept Scientific advancement and proofs of concept

Proofs of concept Scientific advancement and proofs of concept DNA Therapeutics’ first lead molecule derived from Dbait, DT01 - cholesterol-Dbait conjugate, is currently in its 1st-in-human trial in association with radiotherapy to treat patients with local metastatic skin cancer. Like Dbait, it targets the non homologous end joining DNA repair pathway which is the main DNA repair mechanism of the most lethal double strand DNA breaks. The bioactivity of Dbait molecules has been extensively investigated in vitro and in vivo. Their chemical structure and size have been optimized. Their interaction with proteins involved in the NHEJ DSB repair pathway has been proven in vitro. The proofs of concept of DbaitDT01 have been achieved in various human tumors models in animals by local or systemic administration in association with radiotherapy, chemotherapy, or hyperthermia. Figure below illustrates the 1st preclinical proof of concept of Dbait in association with radiotherapy in nude mice xenografted by human head & neck squamous cell carcinoma. A human radio-resistant head & neck squamous cell carcinoma was subcutaneously xenografted on nude mice. Treatment started when the tumors were about 200 mm3 in volume. Dbait molecules were administrated by intratumoral injection 5 hours prior RT at 2Gysession. The treatments were repeated 3 times a week for 5 weeks. Upper left: Overall survival curves: 4 arms were tested : untreated; RT alone; RT + increasing dose of Dbait. Upper right: Statistical analysis of the data: RT arm was used as reference for hazard ratio and p-value calculation. Bottom: Magnetic resonance imaging at mid-course of treatment showed an enhanced necrosis in the xenografted tumor in the presence of lowest dose of Dbait as compared to RT alone. Double blinded histological analysis confirmed the enhanced necrosis and apoptosis. Significant increases of tumor growth delay and of survival have been observed, including complete tumor regression without reoccurrence after more than 300 days, following the administration of Dbait molecules in tumors and combined with fractionated radiotherapy regimens. Biomarkers specific of Dbait's bioactivity and predictive of tumor response to Dbait have been identified and are under development.

Карта сайта

Информационный сайт